<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31022092</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>08</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>08</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1536-4801</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>68</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of pediatric gastroenterology and nutrition</Title>
          <ISOAbbreviation>J Pediatr Gastroenterol Nutr</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Effect of Ketoprofen and ATB-352 on the Immature Human Intestine: Identification of Responders and Non-responders.</ArticleTitle>
        <Pagination>
          <StartPage>623</StartPage>
          <EndPage>629</EndPage>
          <MedlinePgn>623-629</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1097/MPG.0000000000002308</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND OBJECTIVE">The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a broad spectrum of life-threatening adverse effects on the immature gastrointestinal tract. NSAID derivatives exploiting the beneficial effects of biologically active gases, such as hydrogen sulfide (H2S), have been developed. Herein, we determined the effects of ketoprofen and ATB-352, a H2S-releasing ketoprofen derivative, on selected metabolic pathways previously identified to be significantly altered by indomethacin in the human immature intestine.</AbstractText>
          <AbstractText Label="METHODS">Ketoprofen and ATB-352 were tested on human mid-gestation small intestinal explants maintained in a serum-free organ culture system for 48 hours. The expression levels of the representative genes involved in selected metabolic pathways were measured by real-time PCR after a treatment of 48 hours.</AbstractText>
          <AbstractText Label="RESULTS">Tested at a concentration that allows more than 80% inhibition of PGE2 production, ketoprofen was found to be less damaging than indomethacin at an equivalent dosage. However, based on the inducibility of cyclooxygenase-2 transcript expression, we were able to discriminate between responder individuals in which the deleterious effects observed with indomethacin were attenuated, and non-responder specimens in which the effects were similar to those observed with indomethacin. ATB-352 did not induce significant changes compared to ketoprofen on these metabolic pathways.</AbstractText>
          <AbstractText Label="CONCLUSIONS">These results show less damaging effects of ketoprofen compared to indomethacin on the immature intestine and indicate that the intestinal response to this NSAID significantly varies between individuals. However, the results did not allow us to demonstrate a specific beneficial effect of H2S release in organ culture.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Thibault</LastName>
            <ForeName>Marie-Pier</ForeName>
            <Initials>MP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomy and Cell Biology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tremblay</LastName>
            <ForeName>Éric</ForeName>
            <Initials>É</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomy and Cell Biology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wallace</LastName>
            <ForeName>John L</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beaulieu</LastName>
            <ForeName>Jean-François</ForeName>
            <Initials>JF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anatomy and Cell Biology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Pediatr Gastroenterol Nutr</MedlineTA>
        <NlmUniqueID>8211545</NlmUniqueID>
        <ISSNLinking>0277-2116</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>90Y4QC304K</RegistryNumber>
          <NameOfSubstance UI="D007660">Ketoprofen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.99.1</RegistryNumber>
          <NameOfSubstance UI="D051546">Cyclooxygenase 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>XXE1CET956</RegistryNumber>
          <NameOfSubstance UI="D007213">Indomethacin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051546" MajorTopicYN="N">Cyclooxygenase 2</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007213" MajorTopicYN="N">Indomethacin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007421" MajorTopicYN="N">Intestine, Small</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007660" MajorTopicYN="N">Ketoprofen</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors report no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31022092</ArticleId>
        <ArticleId IdType="pmc">PMC6510328</ArticleId>
        <ArticleId IdType="doi">10.1097/MPG.0000000000002308</ArticleId>
        <ArticleId IdType="pii">00005176-201905000-00006</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Berkman ND, Thorp JM, Jr, Lohr KN, et al. 
Tocolytic treatment for the management of preterm labor: a review of the evidence. Am J Obstet Gynecol
2003; 188:1648–1659.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12825006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Overmeire B, Chemtob S.
The pharmacologic closure of the patent ductus arteriosus. Semin Fetal Neonatal Med
2005; 10:177–184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15701582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bjarnason I, Scarpignato C, Holmgren E, et al. 
Mechanisms of damage to the gastrointestinal tract from non-steroidal anti-inflammatory drugs. Gastroenterology
2018; 154:500–514.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29221664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheiman JM.
NSAID-induced gastrointestinal injury: a focused update for clinicians. J Clin Gastroenterol
2016; 50:5–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26524151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Srinivasan A, De Cruz P.
Review article: a practical approach to the clinical management of NSAID enteropathy. Scand J Gastroenterol
2017; 52:941–947.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28587496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallace JL.
Eicosanoids in the gastrointestinal tract. Br J Pharmacol February 27, 2018. Epub ahead of print</Citation>
        </Reference>
        <Reference>
          <Citation>Antonucci R, Zaffanello M, Puxeddu E, et al. 
Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Curr Drug Metab
2012; 13:474–490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22299823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perron N, Tremblay E, Ferretti E, et al. 
Deleterious effects of indomethacin in the mid-gestation human intestine. Genomics
2013; 101:171–177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23261704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L, Rose P, Moore PK.
Hydrogen sulfide and cell signaling. Annu Rev Pharmacol Toxicol
2011; 51:169–187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21210746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallace JL.
Physiological and pathophysiological roles of hydrogen sulfide in the gastrointestinal tract. Antioxid Redox Signal
2010; 12:1125–1133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19769457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L, Rossoni G, Sparatore A, et al. 
Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radic Biol Med
2007; 42:706–719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17291994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiorucci S, Antonelli E, Distrutti E, et al. 
Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology
2005; 129:1210–1224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16230075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiorucci S, Orlandi S, Mencarelli A, et al. 
Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br J Pharmacol
2007; 150:996–1002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2013915</ArticleId>
            <ArticleId IdType="pubmed">17339831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wallace JL, Caliendo G, Santagada V, et al. 
Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology
2007; 132:261–271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17241876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gemici B, Elsheikh W, Feitosa KB, et al. 
H2S-releasing drugs: anti-inflammatory, cytoprotective and chemopreventative potential. Nitric Oxide
2015; 46:25–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25461269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menard D, Arsenault P.
Explant culture of human fetal small intestine. Gastroenterology
1985; 88:691–700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3967805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levy E, Delvin E, Menard D, et al. 
Functional development of human fetal gastrointestinal tract. Methods Mol Biol
2009; 550:205–224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19495706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menard D, Tremblay E, Ferretti E, et al. 
Anti-inflammatory effects of epidermal growth factor on the immature human intestine. Physiol Genomics
2012; 44:268–280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22214601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferretti E, Tremblay E, Thibault MP, et al. 
The nitric oxide synthase 2 pathway is targeted by both pro- and anti-inflammatory treatments in the immature human intestine. Nitric Oxide
2017; 66:53–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28315470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pfaffl MW.
A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res
2001; 29:e45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC55695</ArticleId>
            <ArticleId IdType="pubmed">11328886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llanas B, Cavert MH, Apere H, et al. 
Adverse effects of ketoprofen after intrauterine exposure. Value of plasma determination. Arch Pediatr
1996; 3:248–253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8785563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernandez-Ruiz M, Zlotnik A.
Mucosal chemokines. J Interferon Cytokine Res
2017; 37:62–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5314990</ArticleId>
            <ArticleId IdType="pubmed">28207301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thummel KE.
Gut instincts: CYP3A4 and intestinal drug metabolism. J Clin Invest
2007; 117:3173–3176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2045626</ArticleId>
            <ArticleId IdType="pubmed">17975661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aranda JV, Salomone F, Valencia GB, et al. 
Non-steroidal anti-inflammatory drugs in newborns and infants. Pediatr Clin North Am
2017; 64:1327–1340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29173788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radi ZA, Khan NK.
Effects of cyclooxygenase inhibition on the gastrointestinal tract. Exp Toxicol Pathol
2006; 58:163–173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16859903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rao P, Knaus EE.
Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci
2008; 11:81s–110s.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19203472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burnett BP, Levy RM.
5-Lipoxygenase metabolic contributions to NSAID-induced organ toxicity. Adv Ther
2012; 29:79–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22351432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bregano JW, Barbosa DS, El Kadri MZ, et al. 
Comparison of selective and non selective cyclo-oxygenase 2 inhibitors in experimental colitis exacerbation: role of leukotriene B4 and superoxide dismutase. Arq Gastroenterol
2014; 51:226–234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25296084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hedi H, Norbert G.
5-Lipoxygenase pathway, dendritic cells, and adaptive immunity. J Biomed Biotechnol
2004; 2004:99–105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC548806</ArticleId>
            <ArticleId IdType="pubmed">15240920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian W, Rockson SG, Jiang X, et al. 
Leukotriene B4 antagonism ameliorates experimental lymphedema. Sci Transl Med
2017; 9: eaal3920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28490670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pilotto A, Seripa D, Franceschi M, et al. 
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology
2007; 133:465–471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17681167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Miao X, Tan W, et al. 
Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology
2005; 129:565–576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16083713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleinstein SE, Heath L, Makar KW, et al. 
Genetic variation in the lipoxygenase pathway and risk of colorectal neoplasia. Genes Chromosomes Cancer
2013; 52:437–449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3698944</ArticleId>
            <ArticleId IdType="pubmed">23404351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poole EM, Bigler J, Whitton J, et al. 
Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev
2006; 15:502–508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16537708</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
